Multiple oncology readouts tied to ASCO26 are pointing to expanding options across lung and head-and-neck cancer, with companies using combination strategies aimed at both efficacy and durability. Merck’s partner Kelun-Biotech reported Phase 3 success in a China study of the antibody-drug conjugate sac-TMT (sacituzumab tirumotecan, sacituzumab tirumotecan) paired with a PD-1-targeted immunotherapy in advanced, previously untreated non-small cell lung cancer. The reported 65% reduction in risk of tumor progression, along with a preliminary survival signal, targets a difficult-to-treat population and could accelerate interest in translating the regimen beyond China after additional follow-up. In parallel, ASCO pre-meeting coverage highlighted early head-and-neck cancer data across multiple companies and mechanisms, underscoring how immune modulation remains central to the disease area where resistance to single-pathway approaches is common. A separate pre-ASCO item focused on new data for VEGF bispecifics from BioNTech-BMS and Pfizer/3SBio—another attempt to diversify tumor-immune interactions beyond checkpoint-only strategies as the field competes for trial momentum heading into ASCO’s plenaries and late-breaking sessions.